National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials
News Jul 27, 2007
National Stem Cell Holding, Inc. together with Michael Cohen and Jacob Cohen announced the filing of a provisional patent application for a newly discovered group of cellular derived biomaterials that appear to promote tissue repair in a variety of wound care applications.
These new biomaterials are derived from the company's proprietary stem cell and progenitor cell lines. Preclinical studies with these newly discovered biomaterials appear to enhance the rate of tissue repair and healing and of the strength of healed wounds.
The Company believes that further research and development will clarify indications thus far that these biomaterials may be useful for a wide variety of acute and chronic wounds including but not limited to, burns, surgery related, and diabetes related.
Government Accounting Office (GAO) statistics show a tremendous need for wound care treatment. Each year, according to the GAO, approximately five million Americans suffer from chronic wounds caused by diabetes, circulatory problems and many other conditions.
High blood pressure, or hypertension, is suggested to be one of the leading risk factors for heart disease. The process in which high blood pressure causes heart disease is not completely understood. Now, researchers have found that high blood pressure caused by specific signalling from the brain promotes heart disease by altering stem cells with the bone marrow.READ MORE
13th Annual Conference on Stem Cell & Regenerative Medicine
Mar 07 - Mar 09, 2019